ATOS — Atossa Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $171.67m
- $83.21m
- 37
- 28
- 90
- 50
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -17.2 | -17.8 | -20.6 | -27 | -30.1 |
Depreciation | |||||
Non-Cash Items | 8.63 | 6.43 | 4.83 | 7.12 | 8.35 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.57 | -0.216 | -0.719 | -0.928 | 0.776 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -9.13 | -11.6 | -16.5 | -20.8 | -20.9 |
Capital Expenditures | -0.008 | -0.009 | -0.009 | -0.027 | -0.014 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | — | -4.7 | 0 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.008 | -0.009 | -0.009 | -4.73 | -0.014 |
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 11.3 | 38.6 | 113 | 0 | -1.48 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 2.2 | 27 | 96.8 | -25.5 | -22.4 |